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 Orthopedic wound infections from complex trauma are a prevalent problem.  
Systemic delivery of antibiotics may result in sub-inhibitory concentrations of antibiotic 
in the wound site due to avascular nature of these injuries and can lead to development of 
antibiotic resistant infections.  Local antibiotic delivery can overcome this shortcoming of 
systemic therapy.  A customizable bio-polymer that can be loaded with antibiotics and be 
stimulated to release a drug on demand may provide an improved adjunct clinical therapy 
for preventing/treating infections in complex trauma injuries.  The aim of this study is to 
incorporate iron oxide laden chitosan microbeads into the chitosan sponge to create a 
local delivery composite that is responsive to externally applied electromagnetic 
stimulation.  Composites were evaluated for degradation, antibiotic and representative 
protein elution, antibiotic activity, and biocompatibility.  When excited with ultrasound, 
the composite has a higher burst release of a loaded drug followed by less of a sustained 
release.  Magnetic pulse stimulation increases the release of loaded vancomycin at 3 and 
6 hours of elution but seems to decrease the release of loaded amikacin through 48 hours 
of elution.  Vancomycin and amikacin eluted from the composites was active against 
Staphylococcus aureus and Pseudomonas aeruginosa respectively through 48 hours of 
elution.  These results indicate that the addition of iron oxide containing chitosan 








 The main body of this thesis is a journal article entitled “Preliminary In Vitro 
Results for Chitosan Sponge/Microbead Composite for Stimuli Responsive Antibiotic 
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CHAPTER 1: INTRODUCTION 
 
Statement of Problem 
 Osteomyelitis, a bone infection caused by bacteria or fungi is a common problem 
with complex musculoskeletal trauma in both military and civilian populations [39].  
Without proper treatment, these infections can lead to bacteremia which increases the risk 
of death [36].  Patients with bacteremia have an increased risk of admission to an 
intensive care unit and of in-hospital death [36].  In patients with device related soft 
tissue infections, 94% had cases of secondary bacteremia [36].  With the increasing 
number of prosthetic joint replacements, infections in these joints are a growing problem 
[4].  While the incidence rates of hip and knee replacements are low, approximately 0.5-
1.0% of primary hip replacements, 0.5-2% of primary knee replacements and less than 
1% of primary shoulder replacements become infected, their increased use is causing 
infections from them to become a major cost to healthcare [4, 18]. These numbers rise 
with revisions; there is a 5% infection rate in revision implant replacements and 20% or 
more when the revision is because of an infection [18].  There is also increasing evidence 
that many revision implant replacements deemed “aseptic” at initial clinical assessment 
are in fact infected [37].  The mortality due to hip replacement infections can be as high 
as 10% [4].  Open bone fractures also carry a high risk of infection at 10-50% [60].  A 
retrospective study has shown that all open type III fractures among combat casualties 
were contaminated with bacteria [26].  Among these patients, 37% experienced delayed 
union and 14% resulted in amputation [26]. 
 Wound infections are also becoming harder to treat with the occurrence of 





Resistant Staphylococcus aureus (MRSA), but many other antibiotic resistant bacteria 
species are becoming more prevalent such as vancomycin resistant enterococci [36].  The 
presence of MRSA in wound and bone infections makes them increasingly harder to treat 
and abate because of limited choices of antibiotic [4].  According to the Center for 
Disease Control and Prevention (CDC), 18,650 patients died in hospitals from MRSA 
infections in 2005 [28]. 
 Systemic delivery of antibiotics is not always the most effective delivery method 
for treating infected injury/implant sites due to avascular areas in the body, such as 
around an implant or with complex trauma [21]. This often times results in sub-
therapeutic concentrations of antibiotic at the infection site [7, 9, 22, 40].  Systemic 
antibiotic delivery can also have toxic side effects [7, 9, 21, 22, 40].  Many times 
systemic delivered antibiotics can be ineffective and result in antibiotic resistant 
infections due to relatively low antibiotic concentrations at the infection site.  To 
overcome limitations of systemic delivery in these cases, antibiotic therapy using 
localized delivery systems may be used [21].  Local drug delivery and in particular, local 
delivery that can be controlled from external stimuli (stimuli responsive) and tailored to 
the patient, would be more effective because it can overcome the shortcomings of 
systemic antibiotic therapy through sustained local delivery of antibiotics. 
 Many individual bacteria that are partially resistant to systemic antibiotic therapy 
are much more susceptible to the higher levels of localized antibiotic delivery [21].  
Another advantage of localized antibiotic delivery is that the antibiotic can reach the 
infection site much more quickly than systemic delivery [21].  Stimuli responsive 





drug, and are thus better treatment options over systemic antibiotic delivery [54]. Thus 
local, stimuli responsive drug delivery presents improved options for treating and 
preventing all types of wound infections [21]. 
Treatment of bone infections mainly involves operative debridement, removal of 
all foreign bodies and antibiotic therapy [39].  Intravenous antibiotics are usually 
prescribed for 3 weeks then oral antibiotics are prescribed for 3 weeks [39]. According to 
the East Practice Management Guidelines for prophylactic antibiotic use in open 
fractures, further debridement of the wound after 24-48 hours may be necessary if 
infection is still present [43]. 
Background 
 There are currently many different localized drug delivery vehicles for 
treating/preventing infections.  Each localized delivery vehicle has its own advantages 
and disadvantages in their applications.   
One delivery vehicle is calcium sulfate.  Calcium sulfate acts as an 
osteoconductive scaffold, because of the calcium, and does not need to be removed after 
implantation because it is biodegradable [10, 41, 51, 53].  In some cases, calcium sulfate 
has been shown to promote bone growth and the healing of bone defects [41].  The 
calcium sulfate pellet is reabsorbed in human tissue in 4 to 6 weeks without stimulating 
an anti-inflammatory response [53].  Nelson et al found that bactericidal concentrations 
of tobramycin, 11868 µg/ml on day 1 and 2.5 µg/ml on day 7, could be released by 
calcium sulfate pellets [41].  As of 2005, Wright Medical Technologies makes a 
commercially available kit allowing antibiotic loading of already sterilized calcium 





with tobramycin or vancomyin and result in calcium sulfate pellets that are 4.25% and 
3.64% by weight of antibiotics respectfully [19].  Coripharm, of Dieburg, Germany, also 
makes a carrier material out of calcium sulfate and nanocrystalline hydroxyapatite that 
can be used to carry therapeutic agents [51].  However, calcium sulfate has some 
disadvantages as a local delivery vehicle.  Some studies have shown that there is a short-
term effect of suspected rapid dissolution that can lead to inflammatory reactions within 
the implant site and drainage problems from the wound [11, 32, 51]. 
 Another local antibiotic delivery vehicle is polylactide (PLA)/polylactide-co-
glycolide (PLGA) and polyglycolic acid (PGA).  PLA is a thermoplastic, amorphous 
polymer that is very widely used as a vehicle for local delivery of drugs [35].  PLA and 
PGA are both biodegradable and biocompatible [34, 35].  Poly (L-lactic acid) (PLLA) is 
widely used in the biomedical field [34].  PLLA is used in surgical sutures, implants for 
bone fixation, drug delivery devices, and materials for tissue engineering [34].  However, 
PLA and PGA have some drawbacks as local delivery vehicles.  Nanoparticles 
formulated using PLA and PGA have a rapid uptake by the reticuloendothelial system 
[15].  These particles show a low drug loading efficiency, inability to encapsulate a wide 
range of drugs particularly hydrophilic drugs, and an inability to release their drug 
payload completely [13, 15].  In addition to these drawbacks, PLA and PGA degrade into 
various forms of lactic and glycolic acids [34, 35, 51].  Lactic acid is naturally occurring , 
but the high concentration of acid, both lactic and glycolic, that PLA and PGA creates 
upon degradation lowers the pH of the surrounding environment which can cause 





 Collagen is another polymer used as a drug delivery system.  Collagen is a major 
component of the extra cellular matrix (ECM) which makes collagen biocompatible, 
biodegradable, and useful in designing drug delivery systems [29].  Conventional 
collagen gels containing a drug lead to burst release of the drug [17, 29, 62].  In addition, 
collagen gels exhibit good cell and tissue compatibility [62].  The two most readily 
available forms of injectable collagen gels are suspensions of collagen fibers and non-
fibrillar, viscous solutions of collagen [62].  The issue with collagen mixtures in gels or 
sponges is that the collagen network is much too porous to retain many active agents such 
as antibiotis or biologically active agents. The drugs are released too quickly in a burst 
effect, rather than sustained, possibly leading to cytotoxic concentrations of antibiotics 
and/or resistant antibiotic strains [62].  To improve the drug release profile, secondary 
mechanisms of retention, such as the addition of other solid materials or crosslinking, 
have to be employed into the collagen sponge or gel which add complexity and decrease 
the ease of use [62].  Another drawback is that the randomly oriented gels are too weak 
for surgical manipulation or to bear tensile loads in vivo [62, 64].  These drawbacks make 
collagen a less than ideal drug delivery system. 
 Polymethymetacrylate (PMMA) is another local antibiotic, non-degradable drug 
delivery vehicle.  PMMA beads loaded with antibiotics have been used for many years in 
orthopedic surgery [51].  PMMA with added antibiotics has also been used to lower the 
infection rates of total hip arthroplasty [53].  PMMA is considered to be the gold standard 
in long-term local delivery of antibiotics [42].  However, PMMA is not ideal.  The 
manufacturing of the PMMA beads involves a significant exothermic reaction [53].  This 





be compromised by the manufacturing process [53].  Also, PMMA is a dense acrylic 
polymer and does not degrade meaning not all the loaded antibiotics are available for 
local release [53].  This lack of degradation means that PMMA beads with antibiotics 
implanted during surgery will require an additional surgery for their removal [53].  While 
the PMMA beads are implanted, a fibrouslayer begins to form around the beads which 
can serve as a nidus for infection even with the antibiotics in the beads [53].  Once the 
PMMA beads have been removed, they can leave behind dead space which can also be a 
nidus for infection [53]. 
The drawbacks of all of these delivery systems have led to a search for a better 
local delivery method.  A more biocompatible, degradable, tailorable polymer is 
preferred for a more controllable local drug delivery vehicle.  Chitosan, a biopolymer, is 
a promising local drug delivery biomaterial. 
 During the past 20 years, a substantial amount of work has been reported on the 
polymer chitosan and its potential use in various bioapplications [12].  Chitosan is 
appealing because it is made from an abundant renewable resource, chitin, and is a 
compatible and effective biomaterial that can be used in many applications [12, 27, 30, 
50, 67].  The chitosan molecule is a copolymer composed of N-acetyl-D-glucosamine and 
D-glucosamine units available in different grades depending upon the degree of 
acetylated moieties [12].  The main commercial sources of chitosan are the shell waste of 
shrimp, lobster, krill, and crab [12, 50].  Depending on the source and preparation 
procedure, chitosan‟s molecular weight may range from 300 to over 1000 KD with a 





   The excellent biological properties of chitosan make it a great biomaterial for 
drug delivery systems [12].  It has attracted attention as an excellent mucoadhesive in its 
swollen state and natural bioadhesive polymer that can adhere to both hard and soft 
tissues [12]. A number of colloidal delivery systems based on chitosan have been 
presented for the mucosal delivery of polar drugs, peptides, proteins, vaccines and DNA 
[12].  Clinical tests carried out using chitosan-based biomaterials do not report any 
inflammatory or allergic reactions following implantation, injection, topical application, 
or ingestion in the human body [12].  Chitosan films with low degree of deacetilation 
(DDA) have proven to be good biomaterials for wound healing because they adhere to 
fibroblasts and favor the proliferation of keratinocytes, thereby assisting epidermal 
regeneration [12].  Chitosan is biodegraded in the human body primarily by lysozyme 
[12].  Chitosan is considered to be a non-toxic, biologically compatible polymer that has 
been approved for dietary applications in Japan, Italy, and Finland as well as being 
approved by the FDA for use in wound dressings [12].  Chitosan has also shown 
antimicrobial, hypocholesterolemic, haemostatic, fungistatic, immunity-enhancing and 
antitumor effects, drug delivery, and accelerating calcium and ferrum absorption 
properties [12, 27, 30, 67].  The US military has used a chitosan patch to control bleeding 
in wounds sustained by soldiers in Iraq and Afghanistan [42]. 
 An application of the chitosan films as a local adjunctive therapy for traumatic 
wounds was shown by Noel et al. with in vitro studies. Noel et al. showed that chitosan 
films delivering daptomycin can inhibit S. aureus [42].  The only drawback is that the 
chitosan film shows extremely high initial release with a much smaller release profile at 





infection treatment [42].  The chitosan film has been shown to elute antibiotic much more 
rapidly than antibiotic loaded PMMA, the gold standard in long-term antibiotic release, 
without the need for retrieval surgery [42].  One method to help obtain a more sustained 
release profile of the film was to crosslink the chitosan [55].  However, the processing of 
crosslinking agent is not a simple one.  Many different crosslinking agents, such as 
glutaraldehyde, crosslink chitosan very well but are not biocompatible and in some cases 
are toxic [42, 55].  Genipin has been shown as a potential crosslinking agent for chitosan 
with lower toxicity than glutaraldehyde [38].  She et al. also found that when they 
crosslinked chitosan with citrate, they could make a pH sensitive chitosan film [55].  
They showed that this film would release more drug as the pH decreased [55].  This pH 
sensitivity of chitosan films and other constructs offers the potential for a more 
controllable release profile. 
 Chitosan sponges are another local drug delivery vehicle that has numerous 
applications.  Sponges are soft and flexible materials with a well interconnected 
micropore structure [24].  Chitosan sponges retain a moist atmosphere, high swelling 
capacity, and wound healing without scar formation [24].  Chitosan sponges are a 
degradable antibiotic delivery system that can be loaded immediately before implantation 
as an adjunctive therapy [43].  Oungbho et al. was able to produce pH responsive drug 
delivery using chitosan sponges [45].  This was achieved because chitosan is soluble at 
low pH [45].  Oungbho had a faster release of drug from chitosan sponges in low pH 
media (acidic) compared to sponges in neutral pH media [45].  Also, Noel et al. found 
that amikacin and vancomycin could be loaded into an already fabricated chitosan sponge 





debridement [43].  This study by Noel shows that the chitosan sponge delivery system 
can sustain very high release levels of antibiotics needed for early stage infection 
prevention [43]. 
Chitosan microspheres are another chitosan based local drug delivery vehicle.  
The use of microsphere-based therapy allows drug release to be carefully tailored to the 
specific treatment site through the choice and formulation of various drug-polymer 
combinations [56].  Using innovative microencapsulation technologies, and by varying 
the copolymer ratio and molecular weight of the polymer, microspheres can be developed 
into an optimal drug delivery system which will provide the desired release profile [56].  
Chitosan microspheres are used to provide controlled release of many drugs and to 
improve bioavailability of degradable substances such as protein or enhance the uptake of 
hydrophilic substances across epithelial layers [56].  The crosslinking agent 
tripolyphosphate (TPP) has been shown to increase the sustained release of ampicillin 
from chitosan microspheres [3].  Different crosslinking agents have been used showing 
promising release profiles for many different drugs [1, 3, 16, 25, 48, 49, 56, 63, 68].  
Jiang et al. was able to incorporate iron oxide (Fe3O4) nanoparticles to make magnetic 
chitosan microspheres [25].  This particular advancement is of extreme importance 
because with these nanoparticles, a more controlled, stimuli responsive drug delivery 
might be achieved.  
 Chitosan, in conjunction with other materials, may offer the ability to control drug 
dosing in terms of quantity, location, and time; improved control helps in maximizing the 
therapeutic effect while minimizing side effects [5].  Many different stimuli such as 





triggering systems [5].  Nanoparticles were first developed around 1970 and are defined 
as solid colloidal particles, less than 0.1 µm in size, that consist of macromolecular 
compounds [31].  Nano sized iron oxide (Fe3O4) particulates have emerged as versatile 
materials for different applications due to their magnetic, electronic, photonic and optical 
properties [8].  The addition of iron oxide nanoparticles offers the ability for greater 
control of the drug release profile.   In particular, these molecules produce heat when in 
the presence of an alternating magnetic field [33].   Ultrasound or sonication, can also 
trigger a heating effect in these particles [5].  This heating effect which changes the 
polymer chain arrangement could be used to control the release of a drug from a drug 
delivery system. Iron oxide nanoparticles have the potential to be successfully used in 
many different stimuli responsive drug delivery systems [8, 31]. 
 One major drawback of chitosan is that high DDA chitosan has low solubility in 
aqueous solvents, which limits manufacturing processes and degradation [65].  One way 
to improve this low solubility is with pulsed electric fields (PEF) [65].  The technology of 
PEFs has been widely used for non-thermal pasteurization, enhancing chemical reactions, 
and modifying large molecules [65].  PEFs have also been used to treat cancer and 
permeabilize organelles for drug delivery [44].  The PEF causes the release of calcium 
from the endoplasmic reticulum and can initiate apoptosis [44, 61, 66].  W. Luo et al. 
found that stimulating chitosan with PEFs would significantly deform chitosan, 
decreasing the molecular weight, and significantly damaging the crystalline region of 
chitosan [65].  This deformation of chitosan offers new ways to help control the 







 We hypothesize that a smart stimuli-responsive biomaterial local delivery system, 
with magnetic nano-particles (MNP) impregnated in chitosan microbeads all contained 
within a chitosan sponge, will result in enhanced, tunable local delivery composite for 
infections in-bone defects.  The hypothesis and objectives we developed are based on the 
review of past local drug studies, our own research, and the research of others. 
Objectives 
1. Demonstrate that the chitosan sponge-microbead composite will release 
antibiotic(s) upon stimulation by alternating magnetic field or sonication. 
2. Determine the delivery systems antibiotic(s) elution profile over 72 hours and 
compare results to sponges loaded with the same antibiotic. 






CHAPTER 2: PRELIMINAY IN VITRO RESULSTS FOR CHITOSAN 
SPONGE/MICROBEAD COMPOSITE FOR STIMULI RESPONSIVE 
ANTIBIOTIC DELIVERY  
 
Introduction 
Osteomyelitis is a common problem caused by complex musculoskeletal trauma 
[39].
  
Without proper treatment, it can lead to bacteremia, which increases risk of 
admission to an intensive care unit and death [36].  One cause of bacteremia is medical 
device related soft tissue infections [36].  With joint replacements and revisions 
increasing, infections leading to bacteremia in these joints are also on the rise [4]. 
Currently, a 2% or less infection rate can be found in primary joint replacements, 5% 
infection rate in revisions and 20% or more when the revision is because of an initial 
infection [18].  Open bone fractures also carry an extremely high risk of infection at 10-
50% [60].   
 Wound infections are also becoming much more difficult to treat because of 
increased antibiotic resistance in bacteria.  Systemic delivery of antibiotics is not always 
effective and often do not achieve high antibiotic concentrations [7, 9, 22, 40].  Systemic 
antibiotic delivery can also have toxic side effects and can result in antibiotic resistant 
infections [7, 9, 21, 22, 40].  Due to systemic antibiotic therapy relying on vascularity to 
spread, avascular areas of the body cannot be reached [21].   
 Stimuli responsive local drug delivery presents more controlled options for 
treating and preventing wound infections [21]. Bacteria that are resistant to systemic 
antibiotic therapy are more susceptible to higher levels of localized antibiotic delivery 
and the potential timing of dosage release can be controlled [21].  Another advantage is 





more control over the complete release profile [21, 54].  If an external stimuli can 
stimulate the release of antibiotics, this offers more control over the antibiotic release 
profile than just local delivery [5, 8, 31, 33]. 
There are many different localized drug delivery vehicles for treating infections; 
however, the drawbacks of these delivery systems have led to a search for a better local 
delivery method [10, 11, 13, 15, 32, 34, 35, 51, 53, 62, 64].   Chitosan is appealing 
because it is made from an abundant renewable resource, chitin, and is a compatible, 
biodegradable, effective, and non-toxic biomaterial with many applications [12, 27, 30, 
50, 67].  Chitosan has been approved for dietary applications in Japan, Italy, and Finland 
and by the FDA for use in wound dressings [12].  Chitosan sponges can be loaded 
immediately before implantation as an adjunctive therapy [43].  Also, Noel et al. found 
that amikacin and vancomycin could be loaded at point of care into an already fabricated 
chitosan sponge and provide a sustained release out to 72 hours as adjunctive therapy for 
trauma care [43].  This study by Noel shows that the chitosan sponge delivery system can 
sustain very high release levels of antibiotics needed for early stage infection prevention 
[43].   
 Our preliminary study investigated a chitosan sponge and microbead composite 
that will have the capability of releasing antibiotics upon stimulation by a pulsed 
magnetic field due to the addition of iron oxide nanoparticles, Fe3O4, to the chitosan 
microbeads.  The chitosan microbeads with iron oxide nanoparticles, these nanoparticles 
produce heat in presence of pulsed magnetic fields (PMFs), will be “suspended” inside 
the sponge and are stimuli responsive.  Upon stimulation by pulsed magnetic field, the 





antibiotics According to the East Practice Management Guidelines for prophylactic 
antibiotic use in open fractures, a „„second-look‟‟ at a wound may be performed at 24-48 
hours with subsequent debridement necessary [23].  Ideally, our composite will remove 
the need for the subsequent debridement. 
Based on the needed improvements of infection treatment in orthopedic 
infections, we asked the following questions: Can we fabricate an adaptable, 
cytocompatible and biodegradable chitosan sponge/microbead composite capable of 
absorbing antibiotics, or a representative bone related protein, and eluting them in 
response to either ultrasound or pulsed magnetic field as an adjunct therapy to 
debridement and lavage? Are these composites capable of releasing levels of antibiotic to 
inhibit the growth of Pseudomonas aeruginosa and Staphylococcus aureus, two 
representative bacteria known to infect orthodpedic infections [43]?  
Materials and Methods 
 We investigated the ability of a chitosan sponge and microbead system to deliver 
antibiotics upon outside stimulation over 72 hours. Our composite is made up of a 
chitosan sponge, hydrated with chitosan microspheres that are 50% w/w Fe3O4 
nanoparticles. According to the East Practice Management Guidelines for prophylactic 
antibiotic use in open fractures, a „„second-look‟‟ at a wound may be performed at 24-48 
hours with subsequent debridement necessary [23].  Because of this “second-look” 
between 24-48 hours, our selected elution time points are 1, 3, 6, 24, 48, and 72 hours.  
 The Fe3O4 nanoparticles were made following the methods of Hu et. al[20]. 1.35g 
of FeCl3·6H2O was dissolved in 40 ml of ethylene glycol to form a clear solution.  Then 





Once the reactants were fully dissolved, the solution was transferred into a Teflon-lined 
autoclave vessel with a capacity of 50ml, and heated at 200
o
C for 8 hours.  After the 
autoclave, the products were collected, rinsed with de-ionized water and ethanol several 
times, then dried in a vacuum oven at 60
o
C for 6 hours. 
Chitosan (83% DDA, MW=250kDa) is obtained from Chitinor AS (Norway).  
Chitosan microspheres containing Fe3O4 nanoparticles were made following the 
procedures in Jain et. al[57].  A 4% w/v solution of chitosan, 5% w/v aqueous acetic acid, 
2% w/v Fe3O4 nanoparticles, 5mg/ml antibiotic (either amikacin or vancomycin both 
from MP Biomedicals) was prepared.  This solution is dispersed in a 1:1 mixture of light 
and heavy mineral oil (paraffin oil from Fisher Chemical) containing .013 w/v Span 80 
surfactant (Sigma Life Science).  This oil solution was allowed to mix for approximately 
15 minutes.  Next, genipin (Wako) was added to make the solution 5mM of genipin.  The 
solution was then stirred overnight (approximately 20 hours) allowing the genipin to 
crosslink the chitosan.  After crosslinking, the solution was rinsed with solutions of 
hexanes, methanol, and acetone, separately in this sequence to remove the mineral oil, 
and then allowed to air dry in laboratory chemical fume hood. 
 Chitosan sponges were made following the procedure in Noel et. al[43].  10.0 
grams of Chitofarm S (83% DDA, 250550 Da) chitosan was dissolved in 1% v/v blended 
acid solvent (75/25 lactic to acetic acid).  This solution was allowed to stir for between 1-
4 hours or until the chitosan was dissolved.  Then 35ml of the chitosan solution was 
pipetted into small aluminum weigh dishes.  These dishes were frozen at -80
o
C (Thermo 
Scientific Forma 900 Series -80
o
C freezer) for at least one hour, then placed into a freeze 





dishes formed sponge-like components during the lyophilization.  These sponges were 
neutralized in 0.6 M NaOH for 30-40 seconds, and then rinsed with distilled water until a 
the rinsing solution read neutral (pH of 7) on a pH strip.  The sponges were again frozen 
at -80
o
C and lyophilized a second time for 48 hours.  The chitosan microspheres 
containing amikacin and Fe3O4 nanoparticles were hydrated into the sponges after the 
second lyophilization with either distilled water or a solution of 5mg/ml antibiotic.  Pre-
loaded composites were lyophilized a 3
rd
 time where as point of care composites went 
straight into elution testing. 
 The groups tested are represented in Table 1.  Each elution was performed in 20 
ml of PBS. Three 1 ml samples were taken from each composite (n=3) at every time 
point: 1, 3, 6, 24, 48, and 72 hours.  At each time point, PBS was completely refreshed.  
Samples were frozen until they were analyzed.  For the magnetic pulse, a 17 turn coil 
given 27.8 volts and 12.9 amps with a maximum Vp-p of 1200 volts and producing a field 
pulsed at 109.7 kHz was used.  The magnetic pulse represents a more clinically viable 
stimulation method than sonication so samples were stimulated for 5 min in between each 
time point. The amikacin levels were measures using an Abbott TDx FLx Immunology 
Analyzer.  Vancomycin levels were measured using a protein assay (Pierce BCA Protein 
Assay Kit) or high pressure liquid chromatography (HPLC). Statistical analysis of the 


































pulse for 5 min 
in between 
each time point 
MP 1 Yes No No Yes No 
MP 2 Yes No No Yes Yes 
MP 3 No Yes Yes No No 
MP 4 No Yes Yes No Yes 
 
 
 The biological activity of the sponge eluates were analyzed using turbidity assays.  
Samples were tested to determine if antibiotic is still active against P. aeruginosa (PA 
ATCC 27317, minimum inhibitory concentration (MIC) 6.25-12.5 µg/ml amikacin) or S. 
aureus (UAMS 1 MIC 1.56-3.125 µg/ml vancomycin) depending on whether amikacin or 
vancomycin were eluted, respectfully [43].  Tubes were prepared with trypticase soy 
broth (TSB) and inoculated with respected bacteria [43].  Positive and negative controls 
were used.  The sample eluates were added to the tubes, resulting in a 10x dilution, and 
incubated at 37
o
C for 24 hours [43].  After incubation, the samples were shaken and read 
with a spectrophotometer at 530 nm [43].   
 A protocol modified from ASTM F813-07 “Standard Practice for Direct Contact 
Cell Culture Evaluation of Materials for Medical Devices” was followed in order to 
assess the direct contact biocompatibility of the sponge/microbead composite.  Normal 
human dermal fibroblasts (NHDFs) were seeded at 3.66×10
4
 cells/ml or 1.43×10
5
 
cells/ml and allowed to grow to near confluence on 12 well polystryrene tissure culture 
plates in Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and penicillin (100 units/ml), streptomycin (100 mg/ml), and 





sponge/microbead composites as well as control polyurethane sponges were soaked in 
pre-warmed sterile 1 x PBS for approximately 20 minutes.  Single 8mm diameter sponges 
(n=3) were gently placed in each well in direct contact with the cell monolayer.  Cells 
were incubated for either 1 or 3 days when biocompatibility was assessed with Cell Titer-
Glo® Luminescent Cell Viability assay which measures ATP production. 
 Degradation of the chitosan sponge/microbead composite was determined by first 
recording the mass of each composite sample, placing specimen in 15 containers (one 
sample per container) containing PBS solution supplemented with 1 gm/ml of lysozyme 
(MP Biomedicals).  Then at 2, 4, 6, 8, and 10 days the composites replicate specimen of 





C for two days and finally re-weighed.  Every two day, during the 10 day test 
period, the lysozyme solution was removed and replaced from each sample container.  
The percent degradation was determined from the difference in weights of each 
composite (
𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡−𝑓𝑖𝑛𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡
𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡
).  This is a destructive test so 15 composites were 
used (3 for each time point). 
Results 
 This study attempted to fabricate an adaptable, cytocompatible and biodegradable 
chitosan sponge/microbead composite capable of absorbing antibiotics and eluting them 
in response to pulsed magnetic field as an adjunct therapy to debridement and lavage.  
The point of care loaded sponge/microbead composite initially has a burst release (at 1 
hour) followed by a sustained release (through 72 hours) of antibiotics without 
stimulation.  The magnetic pulse elution results are shown in Figures 1a, 1b, 1c, and 1d.  





vancomycin, the release levels of amikacin are decreased at 3 (655 µg/ml), 6 (191.2 
µg/ml), 24 (89.4 µg/ml), and 48 hours (41.8 µg/ml) compared to non-stimulated 
composites.  However, when magnetic pulse is applied, the levels of vancomycin 
released are increased at 3 (319.4 µg/ml), 6 (150.3 µg/ml), and 72 hours (47.6 µg/ml) 
compared to non-stimulated composites.  The degradation profile of the composite is 
shown in Figure 2.  The composites which are primarily chitosan sponge, degraded to 
approximately 90% weight remaining after 10 days.  The cytocompatibility results are 
shown in Figure 3.  The composites reduced cytocompatibility after 1 day (94%) and 3 
days (92%) when compared to control polyurethane sponge.  The cells from both the 
polyurethane sponges and composites had similar appearances.  
Can these sponge/microbead composites release inhibitory levels of antibiotics to 
inhibit the growth of Pseudomonas aeruginosa (PA) and Staphylococcus aureus?  The 
point of care loaded magnetic pulse activity results are presented in Table 2.  The 
amikacin loaded composites (MP 3 and MP 4 from Table 1) eluted inhibitory levels of 
amikacin against PA for 48 hours and eluted inhibitory levels of amikacin and 
vancomycin against S. aureus for 24 hours.  The vancomycin loaded composites (MP 1 
and MP 2 from Table 3) eluted inhibitory levels of vancomycin against S. aureus for 48 







Figure 1a: Amikacin elution profile in response to magnetic pulse stimulus.  Groups are 
denoted in Table 3. Error bars denote standard deviation. * denotes statistical difference 
(T-test <0.05) from non-stimulated composite (MP 1).  Amikacin was pre-loaded into the 




Figure 1b: Amikacin elution profile in response to magnetic pulse stimulus.  Groups are 
denoted in Table 3. Error bars denote standard deviation. * denotes statistical difference 
(T-test <0.05) from non-stimulated composite (MP 3).  Amikacin was point of care 







Figure 1c: Vancomycin elution profile in response to magnetic pulse stimulus.  Groups 
are denoted in Table 3.  Error bars denote standard deviation. * denotes statistical 
difference (T-test <0.05) from non-stimulated composite (MP 1).  Vancomycin was point 





Figure 1d: Vancomycin elution profile in response to magnetic pulse stimulus.  Groups 
are denoted in Table 3.  Error bars denote standard deviation.  * denotes statistical 
difference (T-test <0.05) from non-stimulated composites (MP 3).  Vancomycin was pre-






Table 2: Activity of composite groups against either PA or S. aureus.  Groups are 















MP 1 +/- +/- +/- +/- +/- +/+ 
MP 2 +/- +/- +/- +/- +/- +/+ 
MP 3 -/- -/- -/- -/- -/+ +/+ 




Figure 2: Degradation profile of chitosan sponge/microbead composite.  Error bars 































Figure 3: Direct contact cell viability results.  Results are reported in luminescence 





 Wound infections are becoming more difficult to treat because of increased 
antibiotic resistant bacteria.  Systemic delivery of antibiotics is not always effective and 
often do not achieve high antibiotic concentrations [7, 9, 22, 40].  Systemic antibiotic 
delivery can also have toxic side effects and can result in antibiotic resistant infections 
while not being able to reach avascular areas of the body or wounds [7, 9, 21, 22, 40].  
Stimuli responsive local drug delivery presents better options for treating and preventing 
wound infections including delivering high levels of antibiotics to avascular areas of the 
body [21]. Bacteria that are resistant to systemic antibiotic therapy are more susceptible 
to higher levels of localized antibiotic delivery [21].  Another potential advantage is local 





infection site more quickly than systemic delivery [21, 54].  This control of elution 
profile is greater with stimuli responsive, local drug delivery. 
 This study does have several limitations.  One major limitation was the limited 
amount of time each sample could be exposed to the pulsed magnetic field.  We were 
limited to providing each sponge only 5 min of “stimulation” in-between time points.  
Another limitation of this study is short investigated elution duration at 72 hours, 
although 72 hours does cover typical wound debridement timing.  Finally, only limited, 
common representative antibiotics were evaluated.  More antibiotics need to be tested to 
further understand the potential of this chitosan microbead/sponge composite. 
 Our study designed and fabricated a chitosan sponge/microbead composite 
capable of absorbing and eluting antibiotics passively with and without stimulation.  As 
previous studies have shown, we recorded a rapid “burst” release of antibiotic (800-1500 
µg/ml) within the first few hours [2, 6, 21, 43, 52].  Compared to the chitosan sponge 
used in Noel et. al, our study shows a similar release profile of both amikacin and 
vancomycin [43].  Our results showed a similar burst release to that of calcium sulfate 
loaded with tobramycin [52].  However, calcium sulfate loaded with tobramycin shows a 
more prolonged release (28 days) of antibiotics than our chitosan sponge/microbead 
composite (3 days) [52].  This chitosan sponge/microbead composite does have 
similarities to the collagen sponge system because both are biodegradable and 
biocompatible [14].  Our composite is capable of being pre-loaded with antibiotics or 
having the antibiotics being loaded at the point of care and controlling the release through 
stimuli where the collagen sponge was only preloaded with antibiotics [14].  The collagen 





has significantly less release at 24 hours (6.9 µg/ml), approximately 25 times less than 
our composite [14]. 
 The activity levels of the antibiotics released from our chitosan sponge/microbead 
composite were similar to previous results with the chitosan sponge [43].  Our activity 
results show that our sponge/microbead composites can elute active levels of amikacin or 
vancomycin for 48 hours. The addition of the chitosan microspheres does not change the 
release of active antibiotic when compared to previous chitosan sponge studies [46, 47, 
58].  Noel et. al was able to elute active levels of vancomycin for 72 hours against a 
different strain of S. aureus (Cowan 1 MIC between 0.5 µg/ml and 1.0 µg/ml) while our 
activity was only for 48 hours against S. aureus (UAMS 1 MIC 1.56-3.125 µg/ml) [43].  
This difference in antibiotic susceptibility may account for the decrease in active 
antibiotics from our composite compared to Noel‟s chitosan sponge [43].    
 The need for more control of local antibiotic delivery to improve clinical 
outcomes was a motivation for this study.  Our preliminary data suggests that our 
sponge/microbead composite can release inhibitory concentration of antibiotic as well as 
provide additional control over the release profile with outside stimuli at 3, 6, and 72 
hours.  We did test ultrasound as a stimulus and it gave more control over the release 
profile than pulsed magnetic field.  However, because ultrasound is not clinically 
relevant, it was not included in this study.  This composite demonstrates the ability to be 
point of care loaded with antibiotics, giving physicians more antibiotic, or other active 
agent, options for treatment.  With further investigations including expanded in-vitro and 
in-vivo evaluation, as well as assessment against more stimuli such as pulsed electric 





more control over the antibiotic release pattern as adjunct therapy in traumatic wounds 








CHAPTER 3: CONCLUSION  
 
 In this preliminary in vitro study, novel chitosan microbead/sponge composites 
were made for pre-loading or point of care loading of antibiotics/proteins for treatment or 
prevention of musculoskeletal infections.  All of these composites show steady 
degradation of approximately 10% total initial weight by 10 days.  Pre-loading 
composites with amikacin seems to increase the sustained release of amikacin from the 
composite compared to a chitosan sponge alone.  However, when a continuous sonication 
stimulus is applied to the amikacin pre-loaded composites, a higher burst release of 
amikacin (3000 µg/ml) is seen followed by less of a sustained release of amikacin when 
compared to non-stimulated, amikacin pre-loaded composites.  These composites, when 
pre-loaded with amikacin, elute inhibitory concentrations of amikacin against 
Pseudomonas aruginosa (PA) but only for 24 hours, regardless of stimulus.   
Pre-loading microbeads with ALP and the composite with vancomycin releases 
bacterial inhibitory concentrations of vancomycin against S. aureus for 48 hours.  
However, when sonication is applied, the composite releases bacterial inhibitory 
vancomycin levels for 24 hours only.  This reduction by 24 hours of bacterial inhibition 
suggests a much faster release of vancomycin due to sonication. Sonication also caused 
an increased initial release of active ALP with a slight decrease in sustained release.  
These increases in burst release with less sustained release coincide with the pre-loading 
amikacin results. 
The results from pre-loading the microbeads and point of care loading the 
composite combined with a magnetic pulse stimulus show interesting results.  The 





and PA respectively through 48 hours with and without stimulus (magnetic pulse).  This 
inhibition of PA for 48 hours is an improvement of 24 hours from the amikacin pre-
loading study.  This suggests that the extra lyophilization procedure involved in pre-
loading the composite reduces the activity of pre-loaded amikacin.  The magnetic pulse 
stimulus seems to increase the sustained elution of vancomycin levels, while decreasing 
the sustained amikacin release levels. 
 The preliminary in vitro data from this study demonstrated that the incorporation 
of genipin cross-linked, antibiotic loaded chitosan microspheres into a chitosan sponge 
creates a tailorable and controllable drug delivery composite that  may show promise for 
in vivo studies and potential translation to clinical evaluations with additional 
refinements.  The ability of the physician to select a specific antibiotic to load into the 
composite and control its release with a stimulus based on patients needs could result in 
more efficacious and faster treatment of infections and a possible reduction in antibiotic 
resistance development in the patient.  While further in vivo and in vitro studies are 
needed to assess the true effectiveness of these stimuli responsive microbead/sponge 
composites, this preliminary study has demonstrated that chitosan microbead/sponge 
composites may be capable of being stimuli responsive and providing sustained local 









CHAPTER 4: FUTURE WORK 
 
 In order to fully evaluate the properties of this chitosan microbead/sponge 
composite, additional in vitro materials characterization tests are needed.  These tests 
include more extended degradation studies beyond 10 days including degradation in 
response to stimuli, more differentiation between the differences in pre-loaded versus 
point of care antibiotic loaded composites with the same stimulus and antibiotic, more 
elution tests on other stimuli such as pulsed electric fields, and more stimuli tests on 
additional antibiotics or other drugs, specifically bone related proteins.  An extended in 
vivo degradation study with various stimuli would provide a more complete degradation 
profile of the composite and local tissue response.  A proof of principle infected mouse 
catheter animal model with various stimuli applied would demonstrate the functional 
efficacy of the composites as local and stimuli responsive antibiotic delivery system for 
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APPENDIX: ULTRASOUND AS STIMULUS TO RELEASE AMIKACIN, 
VANCOMYCIN OR ALKALINE PHOSPHATASE (ALP)  
 
Introduction 
 Ultrasound or sonication has been shown to be a stimulus option for the chitosan 
sponge/microbead composite.  Also, a representative bone growth protein, alkaline 
phosphatase (ALP), was used to assess the release of protein from the composite.  
Therefore, composites loaded with amikacin and composites loaded with vancomycin 
and ALP were tested for elution in response to sonication as well as antibiotic activity 
against PA and S. aureus. 
Materials and Methods 
 The Fe3O4 nanoparticles were made following the methods of Hu et. al [20]. 
1.35g of FeCl3·6H2O was dissolved in 40 ml of ethylene glycol to form a clear solution.  
Then 1.0g of polyethylene glycol 20000 and 3.6g of NaAc·3H2O were added to the 
solution.  Once the reactants were fully dissolved, the solution was transferred into a 
Teflon-lined autoclave vessel with a capacity of 50ml, and heated at 200
o
C for 8 hours.  
After the autoclave, the products were collected, rinsed with de-ionized water and ethanol 
several times, then dried in a vacuum oven at 60
o
C for 6 hours. 
Chitosan is obtained from Chitinor AS (Norway).  For the purposes of this 
experiment, the DDA (83%) and molecular weight (250550 Da) were not intentionally 
changed. Chitosan microspheres containing Fe3O4 nanoparticles were made following the 
procedures in Jain et. al[57].  A 4% w/v solution of chitosan, 5% w/v aqueous acetic acid, 
2% w/v Fe3O4 nanoparticles, 5mg/ml amikacin or representative protein (alkaline 





a 1:1 mixture of light and heavy mineral oil (paraffin oil from Fisher Chemical) 
containing .013 w/v Span 80 surfactant (Sigma Life Science).  This oil solution was 
allowed to mix for approximately 15 minutes.  Next, genipin (Wako) was added to make 
the solution 5mM of genipin.  The solution was then stirred overnight (approximately 20 
hours) allowing the genipin to crosslink the chitosan.  After crosslinking, the solution was 
rinsed with solutions of hexanes, methanol, and acetone, separately in this sequence to 
remove the mineral oil, and then allowed to air dry in laboratory chemical fume hood. 
 Chitosan sponges were made following the procedure in Noel et. al[43].  10.0 
grams of Chitofarm S (83% DDA, 250550 Da) chitosan was dissolved in 1% v/v blended 
acid solvent (75/25 lactic to acetic acid).  This solution was allowed to stir for between 1-
4 hours or until the chitosan was dissolved.  Then 35ml of the chitosan solution was 
pipetted into small aluminum weigh dishes.  These dishes were frozen at -80
o
C (Thermo 
Scientific Forma 900 Series -80
o
C freezer) for at least one hour, then placed into a freeze 
dryer (Labconco Freezone 2.5) and lyophilized for 48 hours.  The chitosan solution in the 
dishes formed sponge-like components during the lyophilization.  These sponges were 
neutralized in 0.6 M NaOH for 30-40 seconds, and then rinsed with distilled water until a 
the rinsing solution read neutral (pH of 7) on a pH strip.  The sponges were again frozen 
at -80
o
C and lyophilized a second time for 48 hours.  The chitosan microspheres 
containing amikacin and Fe3O4 nanoparticles were hydrated into the sponges after the 
second lyophilization with either distilled water or a solution of 5mg/ml antibiotic.  Pre-
loaded composites were lyophilized a 3
rd
 time. 
 Two separate elution tests were performed, one involving the release of just 





phosphatase, ALP, (Table 2).  The groups tested are represented in Tables 1-2.  Each 
elution was performed in 20 ml of PBS. Three 1 ml samples were taken from each 
sponge (n=3) at every time point: 1, 3, 6, 24, 48, and 72 hours.  At each time point, PBS 
was completely refreshed.  Samples were frozen until they were analyzed.  For sonication 
or ultrasound testing, a standard laboratory ultrasonic cleaner (Fisher Scientific FS60H, 
100W, 42kHz) was used.  Ultrasound was used as a basic laboratory experiment to show 
stimuli responsiveness.  The amikacin levels were measures using an Abbott TDx FLx 
Immunology Analyzer.  Vancomycin levels were measured using a protein assay (Pierce 
BCA Protein Assay Kit) or high pressure liquid chromatography (HPLC).  ALP levels 
were measured using an ALP assay. Statistical analysis of the concentrations was 
performed using SigmaPlot. 
 
 















applied after 24 
hour time point 
Am Son 1 Yes No No No 
Am Son 2 Yes Yes No No 
Am Son 3 Yes Yes Yes Yes 
Am Son 4 Yes Yes No Yes 
Am Son 5 No Yes No No 


















Vn Son 1 Yes Yes Yes 





The biological activity of the sponge eluates were analyzed using turbidity assays.  
Samples were tested to determine if antibiotic is still active against P. aeruginosa (PA 
ATCC 27317, minimum inhibitory concentration (MIC) 6.25-12.5 µg/ml amikacin) or S. 
aureus (UAMS 1 MIC 1.56-3.125 µg/ml vancomycin) depending on whether amikacin or 
vancomycin were eluted, respectfully [43].  Tubes were prepared with trypticase soy 
broth (TSB) and inoculated with respected bacteria [43].  Positive and negative controls 
were used.  The sample eluates were added to the tubes, resulting in a 10x dilution, and 
incubated at 37
o
C for 24 hours [43].  After incubation, the samples were shaken and read 
with a spectrophotometer at 530 nm [43].   
Results 
 We attempted to fabricate an adaptable, cytocompatible and biodegradable 
chitosan sponge/microbead composite capable of absorbing antibiotics and eluting them 
in response to either ultrasound or pulsed magnetic field as an adjunct therapy to 
debridement and lavage.  The sponge/microbead composite initially has a burst release 
(at 1 hour) followed by a sustained release (through 72 hours) of antibiotics without 
stimulation. The elution profile of pre-loaded amikacin composites in response to 
sonication is given in Figures 1a and 1b. The non-stimulated composite had 
approximately twice the sustained release level of amikacin (22 µg/ml) compared to the 
control chitosan sponge.  If stimulated by ultrasound, the composite has a higher burst 
release of amikacin, approximately 1.5 times (3020 µg/ml), than the control chitosan 
sponge and non-stimulated composite.  However, when the stimulus is constantly applied 
for 72 hours, the sustained amikacin release of the stimulated composite is reduced to 





addition of the microbeads to form the composite does lead to a higher sustained elution 
of amikacin, approximately 2 times (22 µg/ml), versus the control sponge at 72 hours.   
The elution profile of the pre-loaded vancomycin and alkaline phosphatase (ALP) 
composites with sonication stimulus is shown in Figure 2a and Figure 2b.  Ultrasound 
stimulation increases the burst release of ALP (149.8 ng/ml) while decreasing the 
sustained release of vancomycin when compared to non-stimulated composites at hour 48 
by 57%. 
The activity results for the pre-loaded amikacin sonication elution are presented in 
Table 3.  The sponges release inhibitory levels of amikacin against PA for 24 hours.  The 
pre-loaded vancomycin/ALP ultrasound elution activity results are presented in Table 4.  
The sonicated composites released inhibitory levels of vancomycin against S. aureus for 
24 hours whereas the non-sonicated composites released inhibitory levels of vancomycin 




Figure 1a: Amikacin elution profile with sonication stimulus.  Groups are noted in Table 
1.  * denotes significant difference (Holms-Sidak <0.05) from control sponge (Am Son 








Figure 1b: Amikacin elution profile with sonication stimulus.  Groups are noted in Table 
1. * denotes significant difference (T-test <0.05) from non-stimulated composite (Am 
Son 5).  Error bars denote standard deviation.  Amikacin was only pre-loaded in 




Table 3: Activity for amikacin elution with sonication stimulus against PA ATCC 27317.  




1 hr 3 hr 6 hr 24 hr 48 hr 72 hr 
Am Son 1 - - - - + + 
Am Son 2 - - - - + + 
Am Son 3 - - - - + + 
Am Son 4 - - - - + + 
Am Son 5 + + + + + + 








Figure 2a: Active alkaline phosphatase (ALP) 72 hour elution profile with sonication 
stimulus.  * denotes significant difference (T-test <0.05) from non-sonicated composite 





Figure 2b: Vancomycin 72 hour elution profile with sonication stimulus. * denotes 
significant difference (T-test <0.05) from non sonicated composite (Vn Son 2).  Error 







Table 4: Activity results for vancomycin ALP sonication elution versus UAMS 1 Staph.  




1 hr 3 hr 6 hr 24 hr 48 hr 72 hr 
Vn Son 1 - - - - + + 





 Our study designed and fabricated a chitosan sponge/microbead composite 
capable of absorbing and eluting antibiotics passively with and without stimulation.  As 
previous studies have shown, we recorded a rapid “burst” release of antibiotic (800-3000 
µg/ml) within the first few hours [2, 6, 21, 43, 52].  Compared to the chitosan sponge 
used in Noel et. al, our study shows a similar release profile of both amikacin and 
vancomycin with only slight differences.  This composite showed 1) increased burst 
release of amikacin in response to sonication, 2) decreased sustained release of 
vancomycin in response to sonication, and 3) increased sustained release of amikacin, 
approximately two fold, with the addition of chitosan microbeads containing antibiotic 
and iron-oxide nanoparticles to the chitosan sponge [43].  Our results showed a similar 
burst release to that of calcium sulfate loaded with tobramycin [52].  However, calcium 
sulfate loaded with antibiotics shows a more prolonged release (28 days) of antibiotics 
than our chitosan sponge/microbead composite (3 days) [52].  This chitosan 
sponge/microbead composite does have similarities to the collagen sponge system 
because both are biodegradable and biocompatible [14].  Our composite is capable of 
being pre-loaded with antibiotics or having the antibiotics being loaded at the point of 





preloaded with antibiotics [14].  The collagen sponge system has a higher burst release 
(3800 µg/ml) at hour 1 than our composite, but has significantly less release at 24 hours 
(6.9 µg/ml), approximately 25 times less than our composite [14]. 
 The activity levels of the antibiotics released from our chitosan sponge/microbead 
composite were similar to previous results with the chitosan sponge [43].  Our activity 
results show that our sponge/microbead composites can elute active levels of amikacin or 
vancomycin for 48 hours. Sonication shortens the release of active vancomycin to 24 
hours and the addition of the chitosan microspheres does not change the release of active 
antibiotic when compared to previous chitosan sponge studies [46, 47, 58].  Noel et. al 
was able to elute active levels of vancomycin for 72 hours against a different strain of S. 
aureus (Cowan 1 MIC between 0.5 µg/ml and 1.0 µg/ml) while our activity was for 
UAMS 1 S. aureus (MIC 1.56-3.125 µg/ml) [43].  This difference in antibiotic 
susceptibility may account for the decrease in active antibiotics from our composite 
compared to Noel‟s chitosan sponge [43].   
 The need for more control of local antibiotic delivery to improve clinical 
outcomes was a motivation for this study.  Our preliminary data suggests that our 
sponge/microbead composite can release inhibitory concentration of antibiotic as well as 
provide additional control over the release profile with two outside stimuli.  This 
composite demonstrates the ability to be preloaded or point of care loaded with 
antibiotics, giving physicians more antibiotic or other active agent options for treatment.  
With further investigations including expanded in-vitro and in-vivo evaluation, this 





antibiotic release pattern as adjunct therapy in traumatic wounds and potentially provide 
prophylactic use in other surgical sites. 
 
 
 
